LIMA PATOWARY

Name: LIMA PATOWARY

Designation: ASSISTANT PROFESSOR

Address for Communication: GIRIJANANDA CHOWDHURY INSTITUTE OF PHARMACEUTICAL SCIENCES, HATKHOWAPARA, AZARA, KAMRUP (M) 781017

Mobile No.: 846586569

WA No:

Email: lima@gips-guwahati.ac.in

Sex: Female

Date of Birth: 03/01/1994

Educational Qualifications:

Sl. No.	Examination Passed	Year of passing	Board / Council / University	Specialization
1	HSLC/10th Std.	2010	SEBA	
2	HSSLC/10+2 Std.	2012	AHSEC	
3	Degree (Please Specify)	2017	Dibrugarh University	Pharmacy
4	Master's Degree (Please Specify)	2019	Dibrugarh University	Pharmaceutical Chemistry

Languages known: English, Assamese, Hindi (Read, Write and Speak)

Academic/ Administrative Experience: Teaching experience- 3years and 5 months

List of Publications:

1. Patowary, L., & Borthakur, M. S. (2022). Computational studies of *Bridelia retusa* phytochemicals for the identification of promising molecules with inhibitory potential against the spike protein and papain-like protease of SARS-CoV-2. *Sciences of Phytochemistry*, *1*(1), 29-41.
2. Akhtar, J., & Patowary, L. (2022). *Bambusa vulgaris*: A comprehensive review of its traditional uses, phytochemicals and pharmacological activities. *Sciences of Phytochemistry*, *1*(2), 11-21.
3. Kikon, R., Chetia, D., Borthakur, M. S., Patowary, L., Tayeng, D., & Zothantluanga, J. H. (2022). *In-silico* design and screening of quinolone derivatives against gyrase of *Staphylococcus aureus*. *Current Trends in Pharmaceutical Research*, *9*(1).
4. Patowary, L., Kashyap, P., Chetia, D., & Gogoi, N. (2021). Docking based virtual screening of some new 4-aminoquinolines against PfCRT. *Current Trends in Pharmaceutical Research*, *8*(1).
5. Sangma, C. D., Chetia, D., Borthakur, M. S., Patowary, L., & Tayeng, D. (2022). In-silico design and screening of cephalosporin derivatives for their inhibitory potential against Haemophilus influenza. *Sciences of Phytochemistry*, *1*(2), 1-10.
6. Patowary, L., Sarma, M., Zothantluanga, J. H., & Chetia, D. (2022). Repurposing of FDA approved drugs having structural similarity to artemisinin against PfDHFR-TS through molecular docking and molecular dynamics simulation studies. *Current Trends in Pharmaceutical Research*, *8*(2).

Lima Patowary

Date: 06/01/2023 (Lima Patowary)